<- Go Home
AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Market Cap
$1.3B
Volume
4.3M
Cash and Equivalents
$83.2M
EBITDA
-$232.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$147.5M
Profit Margin
417.51%
52 Week High
$6.51
52 Week Low
$1.89
Dividend
N/A
Price / Book Value
1.36
Price / Earnings
-7.58
Price / Tangible Book Value
1.49
Enterprise Value
$954.6M
Enterprise Value / EBITDA
-4.27
Operating Income
-$229.3M
Return on Equity
16.81%
Return on Assets
-10.43
Cash and Short Term Investments
$495.7M
Debt
$142.2M
Equity
$964.0M
Revenue
$35.3M
Unlevered FCF
-$241.5M
Sector
Life Sciences Tools and Services
Category
N/A